Adagio Medical to Present at TD Cowen Healthcare Conference
Event summary
- Adagio Medical will present at the TD Cowen 46th Annual Healthcare Conference on March 3, 2026, at 2:30 PM ET.
- The company's vCLAS™ Cryoablation System is CE Marked and under evaluation in the FULCRUM-VT U.S. Pivotal IDE Trial.
- FULCRUM-VT trial has fully enrolled 209 patients with structural heart disease.
- Results of the study will be used to apply for FDA premarket approval (PMA) for the vCLAS™ system.
The big picture
Adagio Medical's participation in the TD Cowen Healthcare Conference underscores its strategic focus on advancing its proprietary ULTA ablation technology. The company's efforts to secure FDA approval for its vCLAS™ system come at a time when the demand for innovative solutions for cardiac arrhythmias is growing. The success of the FULCRUM-VT trial could position Adagio as a key player in the catheter ablation market, particularly for treating ventricular arrhythmias.
What we're watching
- Regulatory Progress
- The pace at which Adagio Medical secures FDA premarket approval for its vCLAS™ system following the FULCRUM-VT trial results.
- Commercial Expansion
- Whether Adagio can sustain its commercial momentum in Europe and other geographies while awaiting U.S. approval.
- Clinical Efficacy
- How the outcomes of the FULCRUM-VT trial will impact the adoption of Ultra-Low Temperature Cardiac ablation technology.
Related topics